Alta Sciences

FEBRUARY 19, 2025

Regulatory Guidance for Oligonucleotide Bioanalysis in Drug Development pmjackson Wed, 02/19/2025 - 21:30 The unique physicochemical properties of oligonucleotides require the use of specialized bioanalytical approaches, with key considerations including selectivity and specificity, sensitivity, stability, and matrix effects.

Drug Development 52

Drug Development Clinical Pharmacology Immune Response Drugs 52

Drug Target Review

APRIL 7, 2025

As our understanding of the underlying biology of disease grows more sophisticated, emerging therapies operate on increasingly complex biopathological systems and mechanisms. Safety biomarkers account for adverse effects of a therapy under study. There are several types of biomarkers to consider.

Clinical Development 69

Clinical Development Clinical Trials Clinical Pharmacology Trials 69

Drug Target Review

JUNE 6, 2025

At the forefront of this transformation is Dr Ebrahim Delpassand, a nuclear medicine physician and the driving force behind RadioMedix (RMX), a radiopharmaceutical company focused on developing targeted diagnostics and therapies.

Therapies 100

Therapies Treatment Drug Development Clinical Development 100

Drug Target Review

APRIL 30, 2025

In the rapidly evolving field of cell and gene therapy (CGT), the ability to manage complex biological data, optimise manufacturing processes, and accelerate drug discovery is crucial. How AI is solving CGTs biggest challenges Cell and gene therapy is inherently complex. Kosten Digital was established to bridge this gap.

Drugs 90

Drugs Therapies Clinical Trials Trials 90

The Pharma Data

JUNE 24, 2025

The partnership represents a major financial and strategic milestone for Revolution Medicines, which has built a robust pipeline of targeted therapies aimed at cancers driven by mutations in the RAS family of genes—some of the most prevalent and historically difficult-to-drug oncogenes in human cancer.

Drug Development 40

Drug Development Clinical Trials Therapies Drugs 40

FDA Law Blog: Drug Discovery

NOVEMBER 10, 2024

These studies are crucial because understanding the natural course of a disease helps in designing better clinical trials and defining meaningful endpoints for future drug development. who intend to evaluate a drug, biologic, medical device, or food for medical purposes that targets a rare disease in a clinical trial.

Clinical Development 69

Clinical Development Production Clinical Trials Treatment 69

The Pharma Data

JUNE 24, 2025

This alliance aims to address mounting challenges in the development and commercialization of mAb therapies and gene therapies, particularly those involving AAV vectors. To date, more than 160 monoclonal antibody therapies targeting nearly 100 disease-related proteins have received regulatory approval globally.

Therapies 40

Therapies Biosimilars Compliance Virus 40

Crown Bioscience

JUNE 23, 2025

Drug resistance remains one of the most pressing challenges in oncology drug development, as it is the leading cause of treatment failure. As researchers look to understand and overcome drug resistance, they need precise, controllable, and scalable models that allow them to isolate and study resistance mechanisms effectively.

Drugs 52

Drugs Drug Development Therapies Treatment 52

Drug Target Review

JUNE 9, 2025

A personal journey to Alltrna Michelle Werner’s career has spanned over 20 years in the pharmaceutical industry, where she developed her expertise in oncology drug development at leading companies such as Bristol Myers Squibb, AstraZeneca, and Novartis.

Disease 80

Disease Treatment Engineering Protein Production 80

Drug Target Review

JULY 8, 2025

As Vice President of Oncology Early Development (OED) at AbbVie , she leads the charge on translating bold scientific ideas into real-world impact – and she’s doing it with a focus on some of the most tenacious cancers out there. Checkpoint inhibitors revolutionised cancer therapy; however, significant unmet clinical needs remain.

Therapies 52

Therapies Science Drug Development Treatment 52

Crown Bioscience

JULY 1, 2025

Highly targeted antibody-drug conjugates (ADCs) combine an antibody with a cytotoxic payload, covalently attached via a chemical linker. These “ biological missiles ” represent an exciting new advance in anti-cancer therapies and are one of the fastest-growing segments in oncology drug development.

Drugs 52

Drugs Drug Development Therapies Research 52

Chemical Biology and Drug Design

MAY 10, 2025

Although it is currently only used in veterinary therapy, carprofen proves to be a molecule with a versatile therapeutic potential for human pharmacotherapy. Moreover, the molecule is a target in the drug discovery process for the development of new bioactive compounds.

Small Molecule 100

Small Molecule Drug Development Science Therapies 100

Drug Target Review

JUNE 11, 2025

Drug development is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates. Highlighting data integration.

Drugs 64

Drugs Clinical Trials Drug Development Pharmaceuticals 64

Drug Target Review

DECEMBER 6, 2024

For more: [link] ; [link] ; [link] ; [link] Nina Truter Nina Truter is a translational scientist with a deep focus on understanding mechanisms of action in drug development and leveraging disparate datasets in biotech. In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry.

RNA 52

RNA Drugs Research Science 52

Drug Target Review

DECEMBER 23, 2024

Antibody-drugconjugates (ADCs) represent a significant advancement in drug discovery, combining the precision of monoclonal antibodies with the cancer-killing power of cytotoxic drugs. Wangs research focuses on developing mechanistic mathematical models to quantitatively characterise ADC-induced toxicities.

Research 52

Research Treatment Therapies Drug Development 52

Drug Patent Watch

DECEMBER 9, 2024

This approach has led to the discovery of numerous potential drug candidates. From Lab to Market: The Long Road of Drug Development Once a promising compound is identified, it enters the long and costly process of drug development. Q: How long does a drug patent last?

Drugs 91

Drugs Drug Development Pharmaceuticals Production 91

Drug Target Review

JUNE 17, 2025

For example, a tumour’s resistance to therapy may not stem from its mutational profile alone but from its interaction with surrounding stroma or immune cells – invisible interactions in dissociated, bulk sequencing data. Integrated multiomics is the future The impact on drug development could be profound.

RNA 71

RNA Engineering DNA Disease 71

Drug Target Review

DECEMBER 11, 2024

This issue poses a significant hurdle for drug developers, with no universal protocol currently in place to address these complexities. Such an approach ensures reliable preclinical toxicology data and supports the transition of innovative therapies from the lab to clinical trials.

International 52

International Laboratories Drugs Pharmacokinetics 52

SugarCone Biotech

JUNE 19, 2025

They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attacking these targets have been developed. SCLC generally has a “hot” tumor microenvironment (TME) meaning that it is infiltrated by immune cells, including the T cells that are activated by immune checkpoint therapies.

Therapies 78

Therapies Clinical Trials Treatment Clinical Development 78

Drug Target Review

JULY 10, 2025

Before a compound can become a viable therapy, it must pass a series of tests – not just for potency, but for how it behaves in the body. Absorption, distribution, metabolism, excretion and toxicity – collectively known as ADMET – are among the most critical and challenging hurdles in small molecule drug discovery.

Metabolic Stability 72

Metabolic Stability Drugs Drug Development Small Molecule 72

Alta Sciences

JUNE 26, 2025

Showcasing Breakthroughs in Ocular Safety and Translational Models We were especially honored to have Dr. Makori and Dr. Iwabe present a symposium titled Ocular Toxicology Studies of New Drug Modalities: An Approach to Reduce Animal Use. conference locations. 1] [link] ; This blog was originally published in June 2025.

Drug Development 52

Drug Development Drugs Science Therapies 52

Drug Target Review

MARCH 4, 2025

Knowing a patients subtype or phenotype can be used to guide obesity treatments of all kinds, including drug therapy, devices, bariatric surgery and even diet and lifestyle interventions, Bagnall explains. The research demonstrated that obesity is not one disease, but many; each of which should be treated with different interventions.

Therapies 52

Therapies Treatment Clinical Trials Science 52

The Pharma Data

JUNE 16, 2025

Teva and Fosun Pharma Forge Strategic Partnership to Develop and Commercialize Innovative Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology Teva Pharmaceutical Industries Ltd. This collaboration marks a significant step forward in global oncology drug development. and Shanghai Fosun Pharmaceutical (Group) Co.,

Therapies 40

Therapies Licensing Licensing Treatment 40

Drug Target Review

JULY 11, 2025

Our mission as a company is to build the most impactful technologies that allow researchers and drug developers to understand underlying biology and ultimately use that to impact human health,” he says. Michael Schnall-Levin, Chief Technology Officer and founding scientist at 10x Genomics, has seen this transformation up close.

Molecular Biology 69

Molecular Biology Disease Therapies Bioinformatics 69

Drug Target Review

JANUARY 14, 2025

Nina Truter Nina Truter is a translational scientist with a deep focus on understanding mechanisms of action in drug development and leveraging disparate datasets in biotech. In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry.

Drugs 69

Drugs Protein Expression Science Research 69

Conversations in Drug Development Trends

NOVEMBER 12, 2024

By Amy Raymond, PhD, PMP, Executive Director, Therapeutic Strategy Lead, Rare Disease Cell and gene therapies (CGTs) include cutting-edge approaches that offer the hope of a healthier, happier, and better tomorrow for a wide range of patient populations. Below, we discuss some of these challenges in cell therapy trials.

Therapies 72

Therapies Clinical Supply Clinical Trials Trials 72

Reprocell

DECEMBER 11, 2024

1 Despite the recent scientific advances in therapies for IBD, including ulcerative colitis and Crohns disease, there are still persistent unmet medical needs due to the complexity and chronic nature of these conditions. The existence of this plateau calls for alternative strategies in drug development to attack the problem.

Drugs 52

Drugs Disease Drug Development Therapies 52

SugarCone Biotech

JUNE 27, 2025

They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attacking these targets have been developed. As we’ll see, ASCO 2025 was a breakout conference for B7-H3-targeted therapies. Advanced therapies targeting B7-H3 use different modalities, currently dominated by ADCs.

Therapies 64

Therapies Pharmaceutical Companies Trials Regulations 64

Drug Target Review

DECEMBER 16, 2024

Dr Pooja Hingorani, Senior Medical Director of Oncology Early Development at AbbVie , shares her journey in STEM, from her early days in New Delhi to her impactful career in oncology research and drug development. Opportunities in clinical research and drug development were not always easy to come by.

Medical Schools 52

Medical Schools Clinical Research Drug Development Trials 52

The Pharma Data

JUNE 18, 2025

Pushkal Garg to Lead Unified Research and Development Organization, Signaling Strategic Expansion into Next Phase of RNAi Therapeutics Innovation Alnylam Pharmaceuticals , a global leader in RNA interference (RNAi) therapeutics, has announced the promotion of Pushkal Garg, M.D.,

RNA 40

RNA Clinical Development Science Disease 40

Drug Target Review

OCTOBER 30, 2024

As we continue to evolve our drug characterisation processes at Verseon, we see the extensive use of assembloids as essential enabling technology for the future of all drug development. 22-26 Technically, these findings could apply to both restoration and enhancement of organ function.

Treatment 105

Treatment Disease Clinical Trials Research 105

PPD

JANUARY 15, 2025

As a result, drug developers make better decisions more quickly (removing 50% of study timeline whitespace) to bring new therapies to market faster. Accelerate customer speed to market With a modern and integrated user experience, AI solutions put the right data and insights into the right hands in real time.

Clinical Trials 95

Clinical Trials Trials Clinical Research Drug Development 95

Drug Target Review

MAY 23, 2025

In the ever-evolving landscape of immuno-oncology, managing the side effects of advanced therapies has become just as important as enhancing their efficacy. Existing therapies, such as tocilizumab, work by blocking specific inflammatory pathways but often come with limitations.

Immune Response 52

Immune Response Therapies Treatment Clinical Trials 52

Alta Sciences

JULY 3, 2025

Altasciences At CPHI Americas 2025 pmjackson Thu, 07/03/2025 - 13:41 In the ever-changing drug development world, staying agile is essential to enabling more informed decisions, faster. It’s a challenge that affects a large percentage of new drug candidates—one we’re passionate about helping to solve.

Small Molecule 52

Small Molecule Drug Development Pharmaceuticals Science 52

The Pharma Data

JUNE 27, 2025

These data offer new hope to the CDD community, which has long struggled with a lack of effective seizure control therapies. The lack of approved therapies specifically indicated for CDD means that treatment strategies are often based on off-label use of anti-seizure medications, with limited success.

Trials 40

Trials Treatment Therapies Pharmacokinetics 40

Drug Target Review

JUNE 16, 2025

By complementing traditional analytical methods, it provides a more accurate representation of drug behaviour to support translational and pre-clinical studies. This article explores the principles, applications and future potential of MSI in drug development.

Drugs 52

Drugs Organic Chemistry Laboratories Pharmaceuticals 52

Drug Target Review

JUNE 28, 2025

“My passion for science drew me to DARPin technology, and I was eager to contribute to the development of new DARPin therapies.” . “I joined Molecular Partners four years ago as the Head of Preclinical Pharmacology Platforms,” she says. ” From there, things moved fast.

Science 52

Science Engineering Treatment Clinical Development 52